

Expert Opinion

1. Introduction
2. Therapeutic value of celecoxib in DR and AMD
3. Retinal delivery of celecoxib
4. Polymeric microparticles for sustained celecoxib delivery to the retina
5. *In vivo* effects of celecoxib
6. Conclusion
7. Expert opinion

informa
healthcare

Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes

Aniruddha Amrite, Vidya Pugazhenth, Narayan Cheruvu & Uday Kompella[†]

[†]*University of Colorado at Denver, Pharmaceutical Sciences, 12700 East 19th Avenue, Aurora, CO 80045, USA*

Importance of the field: Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are two major causes of blindness. In these disorders, growth factors such as vascular endothelial growth factor (VEGF) are up-regulated, leading to either enhanced vascular permeability or proliferation of endothelium. While corticosteroid therapies available at present suffer from side effects including cataracts and elevated intraocular pressure, anti-VEGF antibody therapies require frequent intravitreal injections, a procedure that can potentially lead to retinal detachment or endophthalmitis. Thus, there is a need to develop safe, sustained release therapeutic approaches for treating AMD and DR.

Areas covered in this review: This review discusses the pharmacological basis for using celecoxib, an anti-inflammatory drug capable of selectively inhibiting cyclooxygenase 2, in treating AMD and DR. In addition, this article discusses the safety, delivery advantage and efficacy of celecoxib by transscleral retinal delivery, a periocular delivery approach that is less invasive to the globe compared with intravitreal injections.

What the reader will gain: The reader will gain insights into the development of a pharmacological agent and a sustained release delivery system for treating DR and AMD. Further, the reader will gain insights into the influence of eye physiology including pigmentation and disease states such as DR on retinal drug delivery.

Take home message: Transscleral sustained delivery of anti-inflammatory agents is a viable option for treating retinal disorders.

Keywords: age-related macular degeneration, celecoxib, diabetic retinopathy, microparticles, nanoparticles, periocular drug delivery

Expert Opin. Drug Deliv. (2010) 7(5):631-645

1. Introduction

Celecoxib, commercially available as Celebrex[®] (Pfizer, New York, NY), is an anti-inflammatory agent approved for the treatment of rheumatoid arthritis, osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea and familial adenomatous polyposis [1]. It is a selective cyclooxygenase-2 inhibitor that has been investigated for various cancer therapies and is now being investigated for its antiproliferative and anti-vascular endothelial growth factor (anti-VEGF) effects in several cancers and in ocular disorders such as age-related macular degeneration (AMD) [2] and diabetic retinopathy (DR) [3].

1.1 Diabetic retinopathy and age-related macular degeneration

Diabetic retinopathy and AMD are two key prevailing causes of vision impairment today. The two disorders combined account for >60% of cases of blindness in

Article highlights.

- DR and AMD are leading causes of blindness. Both these disorders are associated with an increase in VEGF in the retina. In addition, it has been demonstrated that inflammation plays a key role in the progression of both DR and AMD. Therapies available at present are not sufficient to halt the progression of these disorders.
- Celecoxib, a selective inhibitor of cyclooxygenase 2 enzyme, has been demonstrated to have anti-VEGF activity in the retinal cells. In addition, celecoxib has antiproliferative effects on retinal pigment epithelial and choroidal endothelial cells.
- A problem with effective pharmacotherapy of retinal disorders is the poor delivery of drugs to the retina. Topical and systemic routes are generally ineffective or require high doses and the intravitreal route is associated with several complications that may compromise safety.
- Periocular routes of drug delivery provide effective therapeutic levels of the drug to the retina and are less invasive to the globe as compared with the intravitreal mode of administration.
- For lipophilic drugs such as celecoxib, it has been demonstrated that eye pigmentation reduces transscleral retinal drug delivery, with the effects being more dramatic for slow release delivery systems. On the other hand, disease states such as diabetes increase retinal drug delivery after periocular administration.
- Polymeric microparticles sustain retinal delivery of celecoxib better than nanoparticles.
- Periocular celecoxib microparticles do not cause retinal atrophy or hypertrophy and reduce diabetes-induced retinal oxidative stress, prostaglandin E2 secretion, VEGF expression and vascular leakage.

This box summarizes key points contained in the article.

the US [4]. Diabetic retinopathy is a microvascular pathology of the retina, wherein vascular leakiness and proliferation are implicated in vision impairment [5]. Inflammation is thought to play a critical role in the pathophysiology of DR [6,7]. Several key signs of micro-inflammation such as vessel dilation, exudation of fluids from blood vessels, altered blood flow to the tissues, leakage of proteins and accumulation of leukocytes have been shown to be involved in DR progression [6,8-10]. Administration of aspirin, a non-steroidal anti-inflammatory drug, which is an inhibitor of cyclooxygenase-1 and cyclooxygenase-2, has been shown to reduce vascular leakage abnormalities in diabetic rats [11] and dogs [12], further suggesting that inhibition of inflammation could be a treatment modality for DR. Growth factors are involved at several stages in the progression of DR. Among several growth factors such as basic fibroblast growth factor (bFGF), VEGF, pigment epithelium derived growth factor (PEDF), lens epithelium-derived growth factor (LEDGF) and others, which are thought to be present and active in the retina, VEGF is the one that has been most widely investigated and is thought to have a key role in DR.

There are two forms of AMD, the wet form (~ 20% of the cases) and the dry form (~ 80% of the cases), with more severe vision loss associated with the wet form of AMD [13]. Vascular proliferation is involved in the progression of the wet form of the disease and is termed choroidal neovascularization (CNV). In the pathophysiology of CNV, there is proliferation of the endothelial cells of the choroidal vasculature. The endothelium proliferates and the cells migrate through the Bruch's membrane and into the retinal pigment epithelium (RPE) and the neural retina as the neovascularization progresses. This new blood vessel invasion of the RPE and neural retina is subsequently associated with retinal detachment, retinal atrophy and central vision loss [14].

At present, therapeutic approaches to treat these disorders are limited, although there is a significant interest and research initiative in discovering therapies to combat the progression of these disorders. During the last few years, therapeutic agents have been introduced into the market to treat DR and AMD. Ozurdex, an injectable implant containing dexamethasone, an anti-inflammatory corticosteroid, was approved in 2009 for treating DR. Pegatinib, an anti-VEGF aptamer, and Lucentis, an anti-VEGF antibody fragment, were approved for treating the wet form of AMD in 2004 and 2005, respectively. Thus, it is evident that anti-inflammatory agents and VEGF inhibition are viable therapeutic options for treating DR and AMD. However, all the above therapeutic agents are injected intravitreally. As intravitreal injections by themselves can cause retinal detachment, endophthalmitis and cataracts [15], there is a need to develop alternative strategies for drug delivery. At present, investigations are underway to develop a delivery system that is less invasive and has limited side effects. In addition to new delivery approaches, there is a need for alternative therapeutic agents. For example, corticosteroids, although effective in reducing macular edema associated with DR, may cause cataracts and elevation of intraocular pressure [16]. As described in this paper, transscleral delivery and the use of celecoxib, a cox-2-selective anti-inflammatory agent, might serve as a safer alternative to currently available therapies.

1.2 Role of VEGF in DR and AMD

Impairments to the retinas of DR and AMD patients are caused largely by the over-secretion of various growth factors. Although many growth factors, including basic bFGF, PEDF and VEGF, have been shown to play a role in retinal angiogenesis, VEGF, owing to its potency, is probably the most significant. VEGF has been shown to be upregulated in the retina early in the course of diabetes [17,18]. VEGF is a major contributor to vascular leakage and plays an important role in the pathophysiology of DR – at early as well as more advanced stages. In the early stages VEGF modulates retinal vascular permeability [19-24], whereas in the later stages VEGF plays a critical role in retinal neovascularization [25]. The upregulation of VEGF in diabetes can be related to

several factors, including oxidative stress, inflammation and hyperglycemia, which are all interlinked. The induction of angiogenesis as well as fluid accumulation in macular edema caused by subsequent blood vessel formation can lead to harmful blood retinal barrier leakage or retinal detachment.

Several studies demonstrate an upregulation of VEGF in the fibrovascular membranes associated with AMD and also in RPE of the patients with AMD [26,27]. In addition, animal models for investigating CNV utilize the strategy of overexpression of VEGF in the retina [28-31]. The putative mechanism that leads to choroidal neovascularization probably involves the increased secretion of VEGF from the RPE, which acts on the choroidal endothelial cells to cause proliferation and migration of the endothelium, leading to neovascularization.

Thus, VEGF is a common factor involved in the pathophysiology of both DR and AMD. Anti-VEGF strategies can be effective therapeutic modalities for the treatment of these disorders.

1.3 Cell proliferation in DR and AMD

The proliferation of the endothelial cells in the retina as well as the choroidal vasculature leads to the sight-threatening complications associated with DR and wet AMD. There is also RPE proliferation involved in the progression of AMD as well as proliferative DR [32]. Under normal circumstances, the endothelium in these vascular beds is at rest. However, under the influence of the pathologic growth factors, these cells begin to proliferate [32]. This proliferation can be actively targeted so that subsequent stages such as formation of new blood vessels can be effectively blocked. Antiproliferative drugs that act on a specific phase of the cell cycle and target the proliferating cells could be a beneficial approach for the treatment of both these disorders.

1.4 Upregulation of Cox-2 in diabetic retinas

Among several factors that lead to the upregulation of VEGF in the retinal vasculature, upregulation of VEGF by cyclooxygenases is speculated to be an important factor [3,17,33]. Four isoforms of the Cox enzyme are now known to exist, with differing roles in various normal and pathological conditions; and two of the isoforms, Cox-1 and Cox-2, are predominant and widely studied [34]. Ayalasomayajula *et al.* [33] demonstrated that cyclooxygenase-2 and not cyclooxygenase-1 has a direct effect on the diabetes-induced secretion of prostaglandin E₂ in the retina [33]. The authors incubated retinas *ex vivo* from rats with diabetes of 2-week duration and age-matched control rats with either celecoxib, which is a selective Cox-2 inhibitor, or with SC560, which is a selective Cox-1 inhibitor. Their results demonstrated that retinal PGE₂ secretion was 2.9-fold higher in the diabetic retinas as compared with the controls (Figure 1). When incubated with celecoxib the PGE₂ secretion from diabetic retinas was reduced by ~ 65%, whereas the reduction with SC560 was only 9%. This indicates that the increased secretion of prostaglandins in the retina during diabetes is a

Cox-2-mediated phenomenon, not a Cox-1-mediated phenomenon. This increase could be a result of an increase in the production of the Cox-2 enzyme or increased enzymatic activity. Indeed, Sennlaub *et al.* [35] have demonstrated that Cox-2 is induced in the retina of diabetic rat and mice.

2. Therapeutic value of celecoxib in DR and AMD

2.1 VEGF inhibition by celecoxib

Celecoxib has VEGF inhibitory effects, as demonstrated in several anticancer studies using different cell types. This inhibitory effect of celecoxib on VEGF secretion or expression could be most probably through the inhibition of Cox-2 enzyme.

Celecoxib has been shown to have anti-VEGF effects even in the retinal cells. In a previous study, treatment with celecoxib resulted in a dose-dependent decrease in VEGF expression in the retinal pigment epithelium [2]. ARPE-19 cells were incubated with celecoxib (0 – 10 µM), and VEGF secretion from the cells with and without celecoxib was analyzed after 12 h of treatment [2]. There was a dose-dependent decrease in VEGF mRNA expression as well as VEGF protein secretion with increasing concentrations of celecoxib (Figure 2). The effect on the mRNA expression leveled off at ~ 50% inhibition, whereas there was ~ 45% inhibition in the VEGF secreted from these cell types. The VEGF inhibition in the RPE cells by celecoxib was at concentrations similar to the median IC₅₀ of celecoxib for inhibition of the Cox-2 enzyme (40 – 90 nM) [36], indicating that the inhibition of VEGF could be through a Cox-2 inhibitory mechanism of celecoxib. The inhibition of VEGF was not due to cytotoxicity as the concentrations of celecoxib having cytotoxic effects on the cells are much higher [3]. This VEGF inhibitory effect of celecoxib has potential value in treating DR and AMD and other VEGF-induced neovascular conditions of the eye. The authors, however, have examined VEGF secretion from unstimulated ARPE-19 cells. It is likely that celecoxib might be even superior at inhibiting VEGF secretion that is induced by other stimuli.

2.2 Inhibition of proliferation of RPE and endothelial cells by celecoxib

Another measure of the therapeutic effects of celecoxib on DR and AMD is at the level of cell proliferation. Celecoxib has been demonstrated to have antiproliferative effects on several cell types, including endothelial cells [37-39]. In addition, celecoxib exerts antiangiogenic and antiproliferative effects on cancer cells *in vivo*, including in humans [40,41]. Furthermore, celecoxib has been effective chemotherapeutic agent for colon polyps in several clinical trials [42-45].

Cellular proliferation, particularly proliferation of the endothelium and/or the RPE, is involved in the proliferative stages of DR and in CNV associated with AMD. Amrite and Kompella [46] demonstrated the antiproliferative effects




Figure 1. Secretion of prostaglandin E₂ in control, diabetic control and, celecoxib and SC-560-incubated rat retinas.

Based on data from [33]. Data are presented as mean $\pm$ s.d. for $n = 4$.




Figure 2. Inhibition of VEGF secretion in ARPE-19 cells with increased concentration of celecoxib.

Based on data from [3]. Data are presented as mean $\pm$ s.d. for $n = 4$.

of celecoxib on the retinal pigment epithelial cells (ARPE-19 cells) and the choroidal endothelial cells (RF/6A cells). Celecoxib inhibited the proliferation of ARPE-19 cells and RF/6A cells in a dose-dependent manner with IC₅₀ values of 23 and 13 μ M, respectively. Celecoxib also inhibited VEGF-induced proliferation of RF/6A cells with an IC₅₀ of 20 μ M. The antiproliferative effect of celecoxib on these cell types was probably through a Cox-2-independent mechanism as rofecoxib (another more potent cox-2 inhibitor) had no antiproliferative effects on the cell types at concentrations up to 100 μ M, whereas flurbiprofen (a Cox-1 and Cox-2 inhibitor) had weak antiproliferative effects on the choroidal endothelial cells with IC₅₀ > 100 μ M. In the same study the authors also demonstrated that celecoxib causes a G2-M phase cell cycle arrest in the RPE and choroidal endothelial cells. The concentrations of celecoxib required to have antiproliferative

effects were lower than the concentrations at which celecoxib had cytotoxic effect on these cell types. This antiproliferative effect of celecoxib could be beneficial in the treatment of the proliferative stages of DR and AMD. Thus, the VEGF inhibitory activity of celecoxib as well as the antiproliferative effects on proliferating retinal cells provide a strong rationale for the use of celecoxib in the proliferative disorders of the retina.

3. Retinal delivery of celecoxib

3.1 Oral administration

Oral administration is the most widely used route for delivering drugs. Ayalasomayajula and Kompella [17] have demonstrated that oral administration of celecoxib can reduce diabetes-induced elevations in VEGF and vascular leakage in a rat model. However, the dose required for these effective

levels is very high (50 mg/kg b.i.d.). This is because the oral pathway leads to circulation of the drug systemically in other parts of the body. Therefore, large amounts of the drug must be dosed in order to have an effective amount reaching the retina. This is also true for drugs other than celecoxib.

As cyclooxygenase-2 is expressed in other areas of the body, such as the heart, large doses of celecoxib and its Cox-2-inhibiting mechanisms could cause several side effects, including cardiovascular problems. Similarly, topical approaches (e.g., eye drops) are inefficient because high doses are needed to compensate for drug loss due to precorneal drainage, which can lead to systemic toxicity. Therefore, to avoid systemic effects, a periocular approach of administering the drug by injection closer to the retina for celecoxib delivery was studied [47]. Although intravitreal injections and surgical implants avoid these systemic effects, they are associated with complications such as retinal detachment and cataracts. As the sclera is shown to be more permeable than the cornea and has a large surface area for sustained drug delivery, transscleral routes are emerging as alternatives to topical and intravitreal modes of administration for the treatment of retinal disorders [47]. In this route, drugs are administered adjacent to the sclera and reach the retina by passing the sclera and underlying tissues, including the choroid-Bruch layer and RPE [47].

3.2 Periocular versus systemic administration

Significantly higher levels of the drugs in the retina can be achieved by the transscleral route as compared with the systemic mode of administration [48]. Ayalasomayajula and Kompella [47] demonstrated that celecoxib delivery to the retina is 54-fold higher following subconjunctival administration as compared with systemic administration (Figure 3). The authors also demonstrate that the delivery of the drug to the contralateral eye is similar to the intraperitoneal and subconjunctival routes of administration. Based on their assessments >95% of the celecoxib is available to the ipsilateral retina by local routes, probably direct penetration of celecoxib through the sclera and choroid-RPE and into the retina by the transscleral pathway.

3.3 Pharmacokinetics of celecoxib in the retina following periocular administration

Celecoxib is a low-molecular-mass hydrophobic drug. Ayalasomayajula and Kompella [47] describe the pharmacokinetics of celecoxib in the retina after periocular administration following administration in non-pigmented rats, whereas Cheruvu *et al.* [49] describe the pharmacokinetics of celecoxib after periocular administration in pigmented and non-pigmented rats. The retinal half-life of celecoxib is ~ 6 h and is similar in both the pigmented and non-pigmented rats [49]. Using deterministic compartmental modelling, Amrite *et al.* [50] have demonstrated that celecoxib PK in the retina following periocular administration can be best described by a model incorporating primary elimination

pathways from the retina, choroid-RPE and the periocular tissues. The major elimination pathway for celecoxib (loss to the systemic circulation) after periocular administration is through the periocular circulation and lymphatics, which is about an order of magnitude higher than loss to the systemic circulation by choroidal circulation [50]. Their modeling studies further indicate that suspensions are better than solutions for increased duration of delivery to the retina following periocular administration, which is applicable for celecoxib as well as other drugs. In addition, the authors also demonstrate using simulations that the celecoxib delivery to the retina can be sustained for prolonged periods by designing systems that can slowly release celecoxib after administration into the periocular tissue [50]. Simulations using celecoxib as a model drug have demonstrated that slow release particulate systems with low clearance by the periocular blood and lymphatic circulation are important for better sustainment of celecoxib delivery to the retina following periocular administration [46,51].

3.4 Effect of diabetes

The transscleral delivery of small molecules is dependent on the physicochemical factors of the drug molecule/drug molecule delivery system combination as well as on the physiological or pathophysiological parameters affecting the surrounding tissues. In ocular drug delivery, certain disease states have been shown to affect drug delivery to particular ocular tissues. Öztürk and co-workers have demonstrated that ocular infection and associated inflammation lead to a significantly higher level of antibiotics in the aqueous humor and vitreous humor by the topical ocular or systemic modes of administration [52-55]. Cheruvu *et al.* [56] demonstrated that the delivery of celecoxib to the retina by the transscleral route is significantly enhanced in the diabetic state (Figure 4). In rats with diabetes duration of 2 months, the retinal total exposure (AUC) of celecoxib was 1.5-fold higher in non-pigmented diabetic rats and 2.4-fold higher in the pigmented diabetic rats as compared with the respective normal rats without diabetes. This increased delivery could be a result of the breakdown of the blood-retinal barrier (BRB) as a result of diabetes progression. The authors also demonstrated by using the FITC-dextran leakage assay that there is a 2.4-fold increased permeability of 4 kDa dextran in non-pigmented diabetic rats and 3.5-fold increased permeability 4 kDa dextran in pigmented diabetic rats as compared with the normal rats. This breakdown could occur at the level of the RPE (outer BRB) or at the level of the endothelium (inner BRB). There are conflicting reports in the literature regarding the anatomical location of the blood-retinal barrier breakdown as a result of diabetes. It is also expected to be dependent on the type of tracer used for evaluating the blood-retinal barrier breakdown.

Thus, disease processes, particularly diabetes, can influence retinal drug delivery by the transscleral route. These observations have clinical relevance as blood-retinal barrier




Figure 3. Extent of celecoxib delivery ($AUC_{0-\infty} \mu\text{g.h/g tissue}$) to the ocular tissues following intraperitoneal and periocular injection (3 mg to one eye) in normal Sprague-Dawley rats.

Based on data from [47]. Data are presented as mean $\pm$ s.d. for $n = 4$.




Figure 4. Relative delivery of celecoxib in diabetic rats compared with control rats following periocular injection of celecoxib.

Reproduced with permission from Springer Science + Business Media; [56]. Data are presented as the ratio of the mean AUCs or concentrations for $n = 4$.

breakdown as a result of diabetes progression has also been demonstrated in humans and this could mean higher delivery of celecoxib to the retina by the transscleral route, which is safer than the intravitreal mode of administration [15].

3.5 Effect of pigmentation

Several drugs are known to bind nonspecifically to biomolecules within the body. It has been shown that melanin, a pigment found in the skin and other parts of the body, has an ability to bind to drugs. It is an important consideration for ocular drug delivery as the uveal tract is pigmented and can affect delivery to the inner tissues. Cheruvu *et al.* [49] compared the relative availability of celecoxib in the retina

following periocular administration in pigmented and non-pigmented rats (Figure 5). The total celecoxib exposure (AUC) in the retina was 1.5-fold higher in the non-pigmented rats as compared with the pigmented animals. This is most probably owing to binding of celecoxib to the melanin pigment found in the choroid as celecoxib has been shown to bind to melanin pigment *in vitro*. The authors found that celecoxib could bind to both natural and synthetic melanin *in vitro* with binding affinity of 0.08×10^{-6} M, which is less than that of chloroquine, a drug that binds strongly to melanin, but greater than that reported for drugs such as timolol and norfloxacin, which have also been shown to bind to melanin [57-59]. When celecoxib is delivered using a




Figure 5. Ratio of ocular tissue AUCs (for celecoxib suspension) or tissue concentrations (for celecoxib-PLA particles) between pigmented BN rats and albino Sprague-Dawley rats.

Reproduced with permission from [49]. Copyright © 2008, ARVO. Data are presented as the ratio of the mean AUCs or concentrations for $n = 4$. In the celecoxib-PLA microparticle group, drug levels could not be detected in the contralateral sclera, lens and cornea in albino Sprague-Dawley rats and in contralateral lens and cornea of BN rats.

sustained release system (microparticles) injected in the periocular tissue, the retinal levels are 7.5-fold lower in the pigmented rats at 8 days post-administration as compared with non-pigmented rats, possibly owing to incomplete saturation of pigment binding sites resulting from slow release and low levels of drug delivery. Unlike retinal levels, the celecoxib concentrations are significantly higher in the choroid-RPE of the pigmented rats as compared with the non-pigmented rats. As >95% of celecoxib is delivered locally to the retina following periocular administration, the binding of celecoxib to melanin can have a significant impact on the amount of drug delivered [17]. Such differences in delivery between pigmented and non-pigmented animals have been demonstrated for other drugs, including chloroquine and bromonidine, albeit after topical administration [60-63].

3.6 Relevance of pigmentation with sustained release dosage forms

Owing to the chronic nature of diseases afflicting the posterior segment of eye and owing to the short-half life of several drugs within the vitreous humor [64], most of the developed dosage forms are sustained release dosage forms, including implants [65], scleral plugs [66], fibrin sealant [67], microparticles [3,47,68,69] and nanoparticles [70]. To compare and contrast the effect of pigmentation on sustained delivery versus bolus injection, Cheruvu *et al.* [49] studied the relative delivery of celecoxib between pigmented (Brown Norway [BN]) and albino (Sprague-Dawley [SD]) rats following periocular injection of celecoxib suspension and celecoxib encapsulated

in PLA microparticles. The BN:SD rat ratio of either tissue AUCs (celecoxib suspension study) or concentrations on day 8 (celecoxib-PLA particle study) were estimated. Drug distribution is considered the same in a given tissue between the two strains of rats, if this ratio is equal to one. If the ratio is more than one, there is greater accumulation/delivery in BN rat. If it is less than one, the delivery is lower in BN rat. The authors found that BN:SD rat tissue ratios were the highest in choroid-RPE among all the tissues and the lowest in the retina and vitreous (Figure 5). Greater reduction in BN:SD ratio for retinal and vitreal levels following periocular injection of celecoxib-PLA microparticles (Figure 5) clearly showed the limitation imposed by pigmentation in sustained drug delivery. With a slow release system, drug levels are maintained at low concentrations, which may not be sufficient to saturate the pigment binding sites. For unpigmented tissues such as cornea and lens and less pigmented sclera, BN:SD ratios for celecoxib AUCs in the plain celecoxib dosing study were close to one.

3.7 Effect of the choroid-Bruch layer, lipophilicity and charge

Retinal delivery of celecoxib following periocular administration involves the transscleral pathway. The drug diffuses through the sclera and the choroid-RPE to reach the retina. It is essential to study the permeability and other transport characteristics of these tissues to design better delivery approaches. In one study, the transport permeability of celecoxib and other small molecules such as budesonide, ^3H -mannitol, sodium fluorescein and rhodamine were




Figure 6. Apparent permeability (Papp) of celecoxib across bovine sclera, sclera-choroid and choroid.

Based on data from [71]. Data are presented as mean $\pm$ s.d. for $n = 6$.

determined across bovine and porcine sclera with or without the choroid-Bruch's layer [71]. The order of permeability coefficients was ^3H -mannitol > fluorescein > budesonide > celecoxib > rhodamine 6G [71]. This order showed that hydrophilic molecules are more permeable than lipophilic ones. Also, the presence of the choroid-Bruch's layer reduced the permeabilities [71]. The choroid-Bruch's layer proved to be a more significant barrier than the sclera, hindering the transport of lipophilic cationic solutes more than hydrophilic solutes [71]. Investigation of permeabilities of celecoxib across sclera, sclera-choroid and choroid layers indicated the following. The transport of celecoxib across the sclera was several-fold higher when compared with the choroid layer (Figure 6). This is probably associated with the binding of drug to melanin tissue present in the choroid-Bruch's layer, resulting in less drug being delivered [71]. This study also showed that size of the drug molecule alone does not necessarily determine permeability, as some of these solutes had similar molecular radii but very different permeabilities [71].

On the other hand, charge of the solute also could be important in determining the retinal availability of drugs following periocular administration. Cheruvu *et al.* have demonstrated that the sclera is more permeable to negatively charged solutes as compared with positive ones with the molecules used in that study [71]. This is because the sclera is made up of collagen fibers and proteoglycans that are negatively charged under normal physiological conditions [71]. Thus, positively charged molecules will probably bind better to this layer, resulting in poor transport [71].

Thus, delivery of drugs across the sclera-choroid is better for solute molecules that are neutral or negatively charged as compared with positively charged molecules and it is also better for hydrophilic drugs as compared with the lipophilic ones. Transscleral delivery of celecoxib, a neutral hydrophobic drug, can probably be enhanced by making it more hydrophilic while maintaining its Cox-2 inhibitory activity.

4. Polymeric microparticles for sustained celecoxib delivery to the retina

Diabetic retinopathy and AMD are chronic disorders that require a prolonged duration of therapy. Sustained release delivery systems such as implants as well as particulate systems can be designed that can provide prolonged delivery of the drug to the retina. It is essential to understand the disposition of the drug as well as the delivery system to design systems that can deliver the drugs effectively to the target tissue. Amrite and Kompella [51] investigated the disposition of particulate systems after periocular administration. Their investigations revealed that particulate systems >200 nm in size (diameter) are retained in the periocular tissue at least for 2 months. Small nanoparticles (20 nm) are rapidly cleared from the site of administration after periocular administration and are not suitable for sustained delivery to the retina. Using modeling and simulation, Amrite *et al.* [72] have demonstrated that celecoxib can be delivered to the retina in a sustained manner using particulate systems. Microparticles, because of their lower surface: volume ratio and much lower clearance from the periocular site of administration, probably best sustain the retinal delivery of celecoxib [72]. Ayalasomayajula and Kompella [68] have determined that celecoxib delivery to the retina can be sustained for a period of at least 2 weeks following periocular administration of celecoxib-PLGA microparticles. The solution of celecoxib is unable to sustain retinal celecoxib delivery. Amrite and Kompella [3] have shown that therapeutically effective levels of celecoxib in the retina can be achieved at 2 months post-periocular administration of celecoxib-PLGA microparticles. Thus, particulate systems can effectively deliver celecoxib to the retina and can sustain the delivery for prolonged periods ranging to months.

5. In vivo effects of celecoxib

Celecoxib effectiveness in diabetic rat models has been tested in a few studies [3,17,68]. Following oral administration of




Figure 7. Inhibitory effects of celecoxib-PLGA microparticles on diabetes-induced elevations in: A. retinal PGE₂ (n = 4); B. retinal VEGF (n = 8 – 9); C. vitreous-plasma protein ratio (n = 4); and D. blood-retinal barrier leakage (n = 4). The parameters were estimated 60 days after periocular administration of the placebo or celecoxib-PLGA microparticles to rats. Based on data from [3]. Significantly different from the *diabetic group, the †diabetic plus placebo group, or the §contralateral eye. Data are expressed as the mean ± s.d.

50 mg/kg celecoxib b.i.d., celecoxib effectively inhibited diabetes-induced increase in the expression of VEGF in the retina. Sprague-Dawley rats were injected with streptozotocin (60 mg/kg) in order to induce diabetes [17]. After 8 days of treatment, the rats were killed and retinas were collected and analyzed [17]. Results showed that after induction of diabetes, the VEGF expression in rats was elevated (2.3 ± 0.8 -fold) compared with control rats, but celecoxib effectively lowered the VEGF expression to control levels [17]. This change in expression shows that the inhibitory effects of celecoxib on cyclooxygenase-2 are associated with a reduction in VEGF secretion, which can have benefits in the treatment of DR.

Oxidative stress occurs in the retina as a result of diabetes and is associated with an increase in thiobarbituric acid and 4-hydroxynoneal levels and a decrease in GSH levels. The oxidative stress in turn is associated with increased secretion of VEGF. During synthesis of prostaglandins the Cox enzymes generate oxygen free radicals, which together with other oxidative species resulting because of the increased glucose levels in diabetes can produce oxidative stress. Thus,

inhibition of Cox activity in the retina can be helpful in reducing the associated oxidative stress. In a previous study, a single dose of subconjunctivally administered celecoxib was effective in reducing the oxidative stress in a diabetic model [73]. Fourteen days after treatment, the thiobarbituric acid and 4-hydroxynoneal levels were significantly decreased whereas the GSH levels were increased, reducing the overall oxidative stress and subsequent negative effects contributing to DR [73].

As described in the previous sections, VEGF is an important contributor to the pathology of DR and AMD. VEGF levels in the retina increase as diabetes progresses. These increased VEGF levels lead to increased vascular leakage in the retina. In addition, prostaglandins themselves, especially PGE₂, have been associated with increased vascular permeability. Amrite *et al.* [3] have demonstrated that periocular administration of celecoxib-PLGA microparticles can effectively inhibit diabetes-induced elevations in retinal PGE₂, VEGF and vascular leakage (Figure 7). With 2 months of diabetes in rats, there was a 3-, 1.7- and 2.7-fold increase in




Figure 8. Probable mechanisms for celecoxib effectiveness in AMD and DR. A. Mechanism of choroidal neovascularization in AMD. **B.** Celecoxib inhibits choroidal neovascularization in AMD by inhibiting VEGF secretion as well as inhibiting endothelial cell proliferation. **C.** Changes in retina as a result of diabetes. **D.** Celecoxib inhibits Cox-2 leading to decreased oxidative stress, prostaglandins and decreased retinal VEGF, leading to a decrease in vascular leakage in the retina.

the retinal PGE₂, VEGF and vascular leakage. In the animals that were treated with a single dose periocular administration of celecoxib-PLGA microparticles, there was a significant reduction in the elevated levels of PGE₂, VEGF and vascular leakage with 40, 50 and 50% inhibition, respectively, with celecoxib treatment. In addition, the authors demonstrated that the sustained release particulate system of celecoxib did not lead to any histopathological damage in the retina and

was safe as evidenced by the retinal morphometry analysis and serum clinical chemistry.

6. Conclusion

Celecoxib, a small molecule cyclooxygenase-2 inhibitor capable of inhibiting prostaglandin secretion, VEGF expression and oxidative stress in retinal cells, is a potential new




Figure 9. Selection of drugs for enhanced transscleral retinal drug delivery. Drugs that bind to pigment show low permeability across the choroid layer and potentially retinal pigment epithelium, with the drug delivery differences being more dramatic for slow release systems. By selecting more permeable drugs, transscleral retinal delivery and hence effects can be potentially enhanced.

Arrows indicate solute release or overall permeability. Tissue layers are not drawn to scale.

D1: Drug 1; D2: Drug 2.

treatment for DR and AMD (Figure 8). Celecoxib has been demonstrated to be effective in alleviating the biochemical changes in the retina associated with diabetes. It is effective orally, although large doses are required. Periocular administration of celecoxib can lead to retinal delivery of the drug through the transscleral pathway. The periocular delivery of celecoxib to the retina is several-fold higher as compared with systemic administration. The retinal delivery of celecoxib following periocular administration can be sustained for a few months using sustained-release microparticulate systems. Celecoxib inhibits VEGF mRNA and VEGF secretion from RPE cells *in vitro* at nanomolar concentrations and has antiproliferative effects on choroidal endothelial cells as well as RPE. *In vivo* periocular administration of celecoxib can reduce diabetes-induced oxidative stress in the retina and effectively inhibit diabetes-induced elevations in PGE₂, VEGF and vascular leakage. Thus, celecoxib has the potential to treat DR as well as other proliferative and neovascular diseases of the eye.

7. Expert opinion

AMD and DR together constitute most cases of blindness in the ageing population. There is an unmet need for safer and more effective therapies for the treatment of these disorders. These disorders have some common factors involved in their pathophysiological progression; these include involvement of growth factors such as VEGF, neovascularization, and cell proliferation. Drugs having anti-inflammatory,

antiproliferative and/or anti-VEGF activities can be beneficial in the treatment of the above disorders. Celecoxib is a selective Cox-2 inhibitor that has anti-inflammatory, antiproliferative and anti-VEGF effects in the retina. Celecoxib reduces the secretion of VEGF from the RPE and has antiproliferative effects on the RPE and choroid endothelium. The antiproliferative effects of celecoxib are through a Cox-2-independent mechanism, thus not all Cox-2 inhibitors may be useful for treatment of these disorders. These two effects combined make celecoxib a unique candidate drug for the treatment of AMD and DR. A hurdle in the treatment of retinal disorders is the effective delivery of drugs to the retina. The topical route is ineffective and the systemic route is associated with systemic toxicity because of the high doses required to achieve therapeutic levels in the retina. The intravitreal route can provide effective drug levels but is associated with risks, particularly when multiple injections are required. The periocular route is a safer alternative to the intravitreal route and could be effective for potent drugs including drugs such as celecoxib. Celecoxib can be delivered to the retina by the periocular route of administration and has been shown to be effective in treating diabetes-induced elevations in retinal PGE₂, VEGF and vascular leakage. Celecoxib, when given by the periocular route, reaches the retina by the transscleral pathway. Further, it has been observed that diabetes increases the transscleral delivery of celecoxib to the retina, probably because of the breakdown of the outer blood-retinal barrier. Further, owing to the breakdown of inner blood-retinal barrier in diabetic animals, celecoxib reaches the contralateral

retina in the undosed eye to a greater extent, when compared with normal animals. Thus, the breakdown of the BRB as a result of the progression of diabetes can be utilized for enhanced delivery of drugs such as celecoxib. Celecoxib binds to melanin with moderate affinity and its delivery to the retina is reduced in pigmented eyes as compared with non-pigmented eyes. Thus, pathophysiological factors such as disease state and anatomical and physiologic factors such as pigmentation of ocular tissues can significantly affect the delivery of drugs to the retina by the periocular route. Both AMD and DR require long-term therapy for their management because they are chronic disorders. Use of sustained drug delivery systems is essential for the chronic treatment of these disorders of the retina. The periocular route with sustained drug delivery systems can provide effective celecoxib levels in the retina for a period of months. Further animal studies followed with clinical studies need to be performed to determine conclusively whether celecoxib could be safe and effective in treating the human DR and AMD either by itself or as an adjunct to existing therapies. Based on its mode of action, celecoxib might also be effective in other proliferative and neovascular conditions of the eye, including eye cancers and corneal neovascularization.

With respect to transscleral retinal drug delivery, the drug has to overcome clearance by the circulatory system and permeate across multiple barriers, including sclera, choroid-Bruch's layer and RPE, to reach the neural retina and the vitreous. The target sites for DR and AMD therapies are either in the retina or in the choroid layer. Pigmented choroid and RPE layers are expected to be significant barriers for drugs capable of binding to the eye pigment. Such binding reduces the solute gradients and, hence, drug transport to the neural retina. When low drug concentrations of drug are maintained in the tissue surroundings, as is the case with slow release delivery systems, the relative impedance of neural retinal drug delivery is aggravated further because of pigment binding. Drugs that bind less to the eye pigment or those showing high permeability are expected to be delivered better to the retina by means of the transscleral pathways (Figure 9).

Declaration of interest

The authors received funding from the NIH (grants EY017533 and DK064172).

Bibliography

Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●) to readers.

1. Drug Therapy Guidelines: Pain/Arthritis Celebrex®(celecoxib). Available from: http://securews.bsny.com/wps/wcm/connect/0cc10b804b0ebef28-fea8f649fb47e57/neny_prov_guid_Celebrex.pdf?MOD=AJPERES [Cited 3 November 2009]
2. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. *J Pharmacol Exp Ther* 2008;324(2):749-58
- **This article demonstrates that celecoxib but not rofecoxib has antiproliferative effects in retinal cells.**
3. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE₂, VEGF, and vascular leakage. *Invest Ophthalmol Vis Sci* 2006;47(3):1149-60
- **This is the first report demonstrating the safety and efficacy of celecoxib microparticles in treating diabetic vascular leakage.**
4. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. *Arch Ophthalmol* 2004;122(4):477-85
5. Shah CA. Diabetic retinopathy: a comprehensive review. *Indian J Med Sci* 2008;62(12):500-19
6. Jousen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. *Am J Pathol* 2002;160(2):501-9
7. Jousen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. *FASEB J* 2004;18(12):1450-2
8. Hata Y, Clermont A, Yamauchi T, et al. Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. *J Clin Invest* 2000;106(4):541-50
9. Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. *Invest Ophthalmol Vis Sci* 2000;41(5):1153-8
10. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. *Semin Ophthalmol* 1999;14(4):233-9
11. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol* 2001;88(3):230-5
12. Kern T, Engerman R. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. *Diabetes* 2001;50(7):1636-42
13. Ferris FR, Fine S, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. *Arch Ophthalmol* 1984;102(11):1640-2
14. Kulkarni A, Kuppermann B. Wet age-related macular degeneration. *Adv Drug Deliv Rev* 2005;57(14):1994-2009
15. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. *Prog Retin Eye Res* 2002;21(2):145-51
16. Carnahan M, Goldstein D. Ocular complications of topical, peri-ocular, and systemic corticosteroids. *Curr Opin Ophthalmol* 2000;11(6):478
17. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat

- model. *Eur J Pharmacol* 2003;458(3):283-9
- **This is the first report demonstrating the efficacy of orally administered celecoxib in reducing VEGF expression and vascular leakage in diabetic retinas.**
18. Xu X, Zhu Q, Xia X, et al. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. *Curr Eye Res* 2004;28(4):251-6
 19. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. *Diabetes* 1997;46(9):1473-80
 20. Aiello LP. Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. *Invest Ophthalmol Vis Sci* 1997;38(9):1647-52
 21. Aiello LP. Clinical implications of vascular growth factors in proliferative retinopathies. *Curr Opin Ophthalmol* 1997;8(3):19-31
 22. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. *Ophthalmic Res* 1997;29(5):354-62
 23. Murata T, Nakagawa K, Khalil A, et al. The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. *Lab Invest* 1996;74(1):68-77
 24. Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. *Lab Invest* 1996;74(4):819-25
 25. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. *Am J Ophthalmol* 2004;137(4):668-74
 26. Kliffen M, van der Schaft TL, Mooy CM, de Jong PT. Morphologic changes in age-related maculopathy. *Microsc Res Tech* 1997;36(2):106-22
 27. Kvant A, Alverve PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. *Invest Ophthalmol Vis Sci* 1996;37(9):1929-34
 28. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. *Invest Ophthalmol Vis Sci* 2000;41(11):3582-9
 29. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. *Am J Pathol* 1997;151(1):281-91
 30. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. *Am J Pathol* 2001;158(3):1161-72
 31. Spilbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. *Am J Pathol* 2000;157(1):135-44
 32. Spaide R. Etiology of late age related macular disease. In: Alfaro VD, Liggett PE, Mieler WF, Quiroz-Mercado H, Jager R, Tano Y, editors. *Age related macular degeneration*. Lippincott Williams & Wilkins, Philadelphia, PA; 2006. p. 23-39
 33. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. *Eur J Pharmacol* 2004;498(1-3):275-8
 - **This report demonstrates the superior ability of celecoxib, a selective Cox-2 inhibitor, to reduce prostaglandin E2 secretion from diabetic retinas when compared with SC560, a selective Cox-1 inhibitor.**
 34. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol Rev* 2004;56(3):387-437
 35. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. *Circulation* 2003;108(2):198-204
 36. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. *Proc Natl Acad Sci USA* 1998;95(22):13313-8
 37. Kazanov D, Dvory-Sobol H, Pick M, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. *Clin Cancer Res* 2004;10(1 Pt 1):267-71
 38. Niederberger E, Manderscheid C, Grosch S, et al. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. *Biochem Pharmacol* 2004;68(2):341-50
 39. Lin HP, Kulp SK, Tseng PH, et al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. *Mol Cancer Ther* 2004;3(12):1671-80
 40. Basu GD, Pathangey LB, Tinder TL, et al. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. *Breast Cancer Res* 2005;7(4):R422-35
 41. Soo RA, Wu J, Aggarwal A, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. *Ann Oncol* 2006;17(11):1625-30
 42. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. *N Engl J Med* 2006;355(9):885-95
 43. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. *N Engl J Med* 2006;355(9):873-84
 44. Gadgil SM, Ruckdeschel JC, Heath EI, et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2007;2(4):299-305
 45. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. *J Natl Cancer Inst* 2007;99(7):545-57

46. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. *J Pharmacol Exp Ther* 2008;324(2):749-58
47. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. *Pharm Res* 2004;21(10):1797-804
- **This article provides quantitative evidence for the superiority of transscleral retinal delivery of celecoxib when compared with systemic administration.**
48. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. *Expert Opin Drug Deliv* 2004;1(1):99-114
- **This article provides a comprehensive review of various approaches for transscleral drug delivery to the back of the eye.**
49. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. *Invest Ophthalmol Vis Sci* 2008;49(1):333-41
- **This article was the first to demonstrate that transscleral retinal drug delivery is impeded by eye pigmentation, with the hinderance being greater for slow release delivery systems.**
50. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. *Invest Ophthalmol Vis Sci* 2008;49(1):320-32
- **This article presents pharmacokinetic modeling approaches to predict retinal and corneal delivery of drugs from periocular routes. Also, it demonstrates that similar models can explain the data in rat and rabbit models.**
51. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. *J Pharm Pharmacol* 2005;57(12):1555-63
- **This was the first report demonstrating that whereas 200 nm and larger particles are retained in the periocular space for at least 2 months, 20 nm particles disappear rapidly with a half-life on the order of a few hours.**
52. Öztürk F, Kortunay S, Kurt E, et al. The effect of long-term use and inflammation on the ocular penetration of topical ofloxacin. *Curr Eye Res* 1999;19(6):461-4
53. Öztürk F, Kurt E, Inan ü, et al. Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes. *Int J Pharm* 2000;204(1-2):91-5
54. Ozturk F, Kortunay S, Kurt E, et al. Penetration of topical and oral ciprofloxacin into the aqueous and vitreous humor in inflamed eyes. *Retina* 1999;19(3):218-22
55. Ozturk F, Kortunay S, Kurt E, et al. Effects of trauma and infection on ciprofloxacin levels in the vitreous cavity. *Retina* 1999;19(2):127-30
56. Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. *Pharm Res* 2009;26(2):404-14
- **This article provides quantitative evidence for the differences in transscleral retinal drug delivery in albino as well as pigmented diabetic animal models.**
57. Abrahamsson T, Bostrom S, Brautigam J, et al. Binding of the beta-blockers timolol and H 216/44 to ocular melanin. *Exp Eye Res* 1988;47(4):565-77
58. Ono C, Tanaka M. Binding characteristics of fluoroquinolones to synthetic levodopa melanin. *J Pharm Pharmacol* 2003;55(8):1127-33
59. Ono C, Yamada M, Tanaka M. Absorption, distribution and excretion of ¹⁴C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. *J Pharm Pharmacol* 2003;55(12):1647-54
60. Acheampong AA, Shackleton M, John B, et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. *Drug Metab Dispos* 2002;30(4):421-9
61. Acheampong AA, Small D, Baumgarten V, et al. Formulation effects on ocular absorption of brimonidine in rabbit eyes. *J Ocul Pharmacol Ther* 2002;18(4):325-37
62. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. *Lancet* 1959;2:478-80
63. Salazar-Bookaman M, Wainer I, Patil P. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. *J Ocul Pharmacol Ther* 1994;10(1):217-39
64. Durairaj C, Shah J, Senapati S, Kompella U. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). *Pharm Res* 2009;26(5):1236-60
- **This was the first comprehensive report for predicting vitreal half-life of drugs based on drug physicochemical properties. The article presents a large data set and predictive equations in the albino and pigmented rabbit models.**
65. Aukunuru JV, Sunkara G, Ayalasomayajula SP, et al. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. *Pharm Res* 2002;19(3):278-85
- **This article demonstrates the usefulness of an injectable biodegradable implant for sustained retinal drug delivery.**
66. Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. *Adv Drug Deliv Rev* 2001;52(1):25-36
67. Tsui JY, Dalgard C, Van Quill KR, et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci* 2008;49(2):490-6
68. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. *Eur J Pharmacol* 2005;511(2-3):191-8
- **This article demonstrates that polymeric microparticles of celecoxib inhibit diabetes-induced retinal oxidative damage.**
69. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.

- Invest Ophthalmol Vis Sci
2003;44(3):1192-201
- **This was the first report assessing polymeric nanoparticles for transscleral drug delivery.**
70. Amrite A, Kompella UB. Ocular distribution of intact nano- and microparticles following subconjunctival and systemic routes of administration. *Drug Deliv Tech* 2003;3:62-7
71. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. *Invest Ophthalmol Vis Sci* 2006;47(10):4513-22
- **This was the first report to demonstrate that choroid layer, independent of RPE, is a significant barrier for transscleral retinal drug delivery.**
72. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. *Mol Vis* 2008;14:150-60
- **This was the first report demonstrating that small nanoparticles (20 nm diameter) rapidly escape into the systemic and lymphatic circulations from the periocular site, explaining their short half-life at the site of administration.**
73. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. *Eur J Pharmacol* 2005;511(2-3):191-8

Affiliation

Aniruddha Amrite¹, Vidya Pugazhenth²,
Narayan Cheruvu³ & Uday Kompella^{†2}

[†]Author for correspondence

¹Quintiles, Inc.,

Clinical Pharmacology,

6700 W 115th Street,

Overland Park, KS 66211, USA

²University of Colorado at Denver,

Pharmaceutical Sciences,

12700 East 19th Avenue,

Aurora, CO 80045, USA

Tel: +1 303 724 4028; Fax: +1 303 724 4666;

E-mail: Uday.Kompella@ucdenver.edu

³Covidien,

Clinical Pharmacology,

675 McDonnell Blvd,

Hazelwood, MO 63042, USA